Press coverage about Anthera Pharmaceuticals (NASDAQ:ANTH) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.981937492579 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Anthera Pharmaceuticals, Inc. (ANTH) projected to achieve earnings growth of 77.80% for this year (wallstreetinvestorplace.com)
- Shares of Anthera Pharmaceuticals, Inc. (ANTH) are value at $0.31 (wallstreetmorning.com)
- Stock Analysts: Should You Listen?: Anthera Pharmaceuticals, Inc. (ANTH) (nasdaqexpress.com)
- Anthera Pharmaceuticals, Inc. (ANTH) – Technical Roundup (wallstreetmorning.com)
NASDAQ:ANTH traded up $0.01 during mid-day trading on Monday, reaching $0.33. 1,466,292 shares of the stock were exchanged, compared to its average volume of 2,793,698. The firm has a market cap of $7.44, a P/E ratio of -0.09 and a beta of 2.78. Anthera Pharmaceuticals has a 1-year low of $0.30 and a 1-year high of $3.36.
A number of brokerages recently weighed in on ANTH. Zacks Investment Research cut shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Piper Jaffray cut shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research note on Monday, March 12th. HC Wainwright reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a report on Tuesday, March 6th. Roth Capital started coverage on Anthera Pharmaceuticals in a report on Wednesday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, Jefferies Group reaffirmed a “hold” rating and set a $0.50 target price on shares of Anthera Pharmaceuticals in a report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Anthera Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $4.06.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3344183/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-anthera-pharmaceuticals-anth-stock-price.html.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.